STOCKHOLM, Sweden, April 14, 2003 (PRIMEZONE) -- Biora's Board of Directors have decided to release the report for the first quarter 2003 on April 25, 2003.
Biora develops manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain(R)Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are listed on the "O-list" of the Stockholm Stock Exchange in Sweden.
This press release may contain certain forward- looking statements that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward looking statements and are more fully discussed in periodic reports filed with Securities and Exchange Commission.
For further information, please contact:
- Svante Lundell, CFO and Investor Relations, Biora +46-70 532 30 65
- Donna Janson, President and CEO of Biora, tel: +46- 40-32 12 28
- http://www.biora.com
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/04/14/20030414BIT00290/wkr0001.doc
http://www.waymaker.net/bitonline/2003/04/14/20030414BIT00290/wkr0002.pdf